B+
Bull case
20%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
OKUR
OnKure TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-01
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+77.2
Score
AI commentary
Primary filing and earnings-release context is strong, but recent-news coverage, social coverage, analyst revisions, options data, short interest, employee sentiment, and direct peer evidence are unavailable or insufficiently supported. The Q2 update is strategically constructive on runway and pipeline timing, yet the absence of clinical data and near-term proof points keeps this a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-09-01
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-30eventH1 2027 IND submissions for OKI-355 and OKI-345High impact
OnKure reports that both next-generation PI3Kα pan-mutant selective programs remain in IND-enabling activities, with FDA submissions planned for the first half of 2027 [#SEC-8K-2026-08-04]. Execution against this timeline is the primary identifiable value inflection, but the packet provides no clinical efficacy data.
2026-11-30catalystCash runway reduces near-term financing pressureHigh impact
The Q2 update reported $176 million of cash, cash equivalents and marketable securities, expected to fund operations into 2029 [#SEC-8K-2026-08-04]. This lowers immediate dilution risk but does not reduce pipeline or regulatory execution risk.
2027-09-01catalystAdvancement of the next-generation PI3Kα pipelineHigh impact
OKI-355 is being advanced in vascular anomalies and OKI-345 in breast cancer, with management citing selective mutant PI3Kα inhibition as the development rationale [#SEC-8K-2026-08-04]. The upside remains highly dependent on regulatory progress and eventual clinical validation.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-01 • Updated nightlySource: Internal modelMethodology